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The isolation and primary structure of intestinal neuropeptide Y (NPY) is described. The peptide was puri- 
fied from porcine intestinal extracts using a chemical assay and radioimmunoassay for NPY. The amino 
acid sequence of this peptide is: Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Aia-Pro-Ala-G~u-Asp-~u- 
Ala-Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-~u-I~e-Thr-Arg-Gln-Arg-Tyr-NH,. This indicates that 
the structure of intestinal NPY is identical to the NPY of brain origin. 
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1. INTRODUCTION 
Neuropeptide Y (NPY), a 36 amino acids pep- 
tide, was originally isolated from porcine brain us- 
ing a chemical assay method based on the detection 
of the C-terminal amide structure fl]. NPY has 
structural similarities to the pancreatic polypeptide 
and peptide YY (PYY) [2]. The peptide exhibits 
potent biological activities such as vasoconstriction 
[3] and inhibition of electrically-stimuiated smooth 
muscle contraction ]4,5]. Central administration 
of NPY induces lowering of blood pressure, 
respiratory and heart rates [6]. NPY coexists with 
catecholamines [7,8] and may modulate 
catecholamine release [9]. NPY is one of the most 
abundant neuropeptides in mammalian brains 
vol. 
results of a specific immunoassay for NPY rev- 
ealed that a NPY-like peptide is present in porcine 
intestinal extracts. We report here the isolation and 
characterization of this peptide. 
2. MATERIALS AND METHODS 
Thermolysin was obtained from Daiwa Kasei 
K.K. Osaka and polyamide thin layer plates from 
Schleicher & Schtill. 
Immunochemical studies suggest that NPY is 
also present in gut [ll], heart [12], pancreas [13], 
adrenal medulla [ 141, and reproductive tract [ 151. 
However, chemical structure of the immunoreac- 
tive NPY has previously not been identified. The 
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NPY was determined by the amount of tyrosine 
amide released on treatment of samples with ther- 
molysin using a chemical assay method described 
earlier [16] and by using a radioimmunoassay for 
NPY [ 171. High-performance liquid chromatog- 
raphy (HPLC) was performed in a Waters instru- 
ment using reversed-phase PBondapak C~S and 
phenyl columns under chromatographic onditions 
described in the legends to fig.l-3. Amino acid 
analyses were performed with a Beckman 121 
amino acid analyser after hydrolysis of samples in 
5.7 M NC1 containing 0.5% phenol at 110°C for 
24 h. Step-wise sequencer degradation of the intact 
peptide was carried out in a Beckman 690 D liquid- 
phase sequencer in the presence of glycine- 
precycled polybrene [ 181. Phenylthiohydantoin 
derivatives were identified by HPLC [19]. 
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3. RESULTS 
3.1. Isolation procedures 
Intestinal NPY was isolated from a starting 
material obtained as a side fraction during the final 
purification step for porcine secretin [20]. Briefly, 
porcine upper intestines (4000 kg) were boiled, 
frozen, minced and extracted with 0.5 M acetic 
acid for 18 h. Peptides in the extract were ad- 
sorbed onto alginic acid, eluted with 0.2 M HCl 
and precipitated with NaCl at saturation. The pep- 
tide precipitate was further purified by extraction 
with 66% ethanol, gel chromatography on 
Sephadex G-25 and extraction with methanol. The 
methanol-soluble fraction was subjected to ion ex- 
change chromatography on a CM-cellulose col- 
umn. The secretin-containing fraction (450 mg) 
was subjected to counter-current distribution (200 
transfers) for final purification of secretin. 
Secretin was found between 60-100 transfers (20) 
and PYY and NPY were found between 1-59 
transfers. Fractions containing PYY and NPY 
were combined and the phases were coalesced by 
addition of ethanol. The solution was kept at 
- 20°C overnight. The salts that had precipitated 
were removed by filtration and the filtrate was 
diluted with 15 volumes of water and the peptides 
were adsorbed onto alginic acid at pH 2.7 and 
eluted from the alginic acid with 0.2 M HCl. The 
chloride ions in the eluate were exchanged for 
acetate on a DEAE Sephadex A-25 column and the 
effluent was lyophilized. This step yielded 223 mg 
of the starting material for the purification of PYY 
and NPY. 
The starting material was further purified by 
chromatography on a CM-cellulose column in 
0.03 M ammonium bicarbonate (pH 8.0). Frac- 
tions containing PYY and NPY were pooled and 
lyophilized. This material (29 mg) was then sub- 
jected to HPLC on a reversed-phase pBondapak 
C-18 column, first eluted with 36% ethanol con- 
taining 0.2% acetic acid and 5 mM ammonium 
acetate, and then with 80% ethanol containing 
0.2% acetic acid and 5 mM ammonium acetate. 
PYY was eluted with the first buffer in a major 
HPLC peak and a total of 5 mg of pure PYY was 
obtained after lyophilization. NPY was found in 
the fraction eluted with the second buffer and this 
fraction (8 mg) was subjected to further purifica- 
tion on the same HPLC column using a linear gra- 
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dient system of 0.12% trifluoroacetic acid/water 
and 0.1% trifluoroacetic acid/acetonitrile (fig. 1). 
Intestinal NPY was eluted at the position identical 
to brain NPY in the HPLC. The lyophilized frac- 
tion containing NPY was subjected to the final 
purification on a reversed-phase PBondapak 
phenyl column (fig.2). This step yielded a total of 
0.2 mg pure intestinal NPY. 
Fig.1. Reversed-phase HPLC profile of the NPY 
fraction (4 mg) on a BBondapak Crs column (7.9 x 
300 mm). Solvent system: A, 0.12% CFsCOOH/HsO; 
B, 0.1% CFsCOOH/CH&N (B: 25-50%). Flow rate, 
2 ml/min. The dotted lines indicate the gradient profile. 
The peak (hatched area) contained NPY. 
______-- 
____/-- ______---- ___----- 
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Fig.2. Reversed-phase HPLC profile of the NPY 
fraction (fig.1) on a ,uBondapak phenyl column (3.9 x 
300 mm). Flow rate, 1 ml/min. Other conditions are as 
described in fig.1. 
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3.2. Structural analysis 
The results of amino acid analysis suggested that 
the peptide consisted of 36 amino acid residues. 
The amino acid composition of the intestinal pep- 
tide was identical to that of brain NPY. The pep- 
tide contained an N-terminal tyrosine and a C- 
terminal tyrosine amide, which were also identical 
to those of porcine NPY of brain origin. Further, 
tryptic fragments of the intestinal peptide were 
found to be eluted at the positions corresponding 
to those of tryptic fragments of brain NPY in 
HPLC. Finally, Edman degradation of the intact 
peptide in a Beckman 890 D liquid-phase se- 
quencer yielded the amino acid sequence up to the 
last residue (fig.3), establishing the intestinal pep- 
tide to be identical to NPY of brain origin. 
motility of the colon [21]. These actions are not 
blocked by adrenergic blocking agents. NPY may 
therefore act directly on the vascular and intestinal 
walls and exert biological actions such as 
vasoconstriction and inhibition of colonic motility. 
PYY is present in the intestine, in considerably 
larger amounts than NPY. PYY is confined in the 
endocrine cells of intestine. This peptide also 
causes a potent colonic vasoconstriction and in- 
hibition of colonic motility [22]. PYY may thus ex- 
ert its actions via an endocrine route. Since both 
peptides are structurally very similar [2], it is possi- 
ble that NPY and PYY interact with the same 
receptors in the gut and exert their actions through 
the two different pathways, one via a neural and 
the other an endocrine route. 
4. DISCUSSION REFERENCES 
The results of specific radioimmunoassay for 
NPY indicated that a side fraction obtained during 
the purification of secretin from porcine intestinal 
extracts contained a high concentration (1.4 nmol/ 
mg) of immunoreactive NPY. The antibodies used 
for the assay did not crossreact with PYY known 
to be present in the same fraction. We therefore 
decided to isolate the immunoreactive NPY from 
this fraction. After a successive HPLC step, the 
product obtained was subjected to structural 
analysis which revealed the peptide structure to be 
identical to the NPY of brain origin. Thus, NPY 








The physiological roles of NPY in the 
gastrointestinal tract have not been established. 
NPY nerves are widely distributed throughout the 
gut, particularly, in the muscle layers and around 
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Fig.3. The complete amino acid sequence of 
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